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Abstract  27 
Background: Although interest in biomarkers in the nitrate-nitrite-NO pathway has recently 28 
increased, associations between nitrite (NO2
−
), nitrate (NO3
−
) and asthma, allergic 29 
sensitization and rhinitis remain unclear. 30 
Objective: To evaluate the associations between NO2
−
/NO3
−
 and exhaled fraction of nitric 31 
oxide (FENO) levels with asthma, allergic sensitization and rhinitis. 32 
Methods: Plasma and exhaled breath condensate (EBC) NO2
−
/NO3
−
 and FENO levels were 33 
measured in 523 adults of the French Epidemiological study on Genetics and Environment of 34 
Asthma. Allergic sensitization was defined by a positive skin prick test for at least one 35 
aeroallergen. Subjects were classified as non-sensitized, sensitized and as having allergic 36 
rhinitis.  37 
Results: Plasma NO2
−
/NO3
−
 level was unrelated to any disease phenotypes. EBC NO2
−
/NO3
−
 38 
level was unrelated to any asthma phenotypes. EBC NO2
−
/NO3
−
 and FENO levels were 39 
correlated in sensitized subjects only (r=0.21±0.10, p=0.01). EBC NO2
−
/NO3
−
 and FENO levels 40 
were higher in sensitized than in non-sensitized subjects (adjusted GM (95%CI): 2.36 (1.96; 41 
2.84) vs.1.72 (1.38; 2.14) µmol/mg proteins, p=0.008; and 18.3 (16.7; 20.0) vs.14.8 (13.3; 42 
16.5) ppb, p=0.0006 respectively), with gradual relationships from sensitized subjects to those 43 
with allergic rhinitis (p<0.0001).  44 
Conclusion: Results suggest that EBC NO2
−
/NO3
−
 and FeNO levels may be considered as 45 
biological markers of intensity of allergic sensitization and rhinitis. 46 
 47 
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condensate, total nitrite/nitrate, exhaled fraction of NO. 49 
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Introduction 51 
The interest in measuring biological markers in exhaled breath condensate (EBC) in 52 
epidemiological studies on respiratory diseases has increased in the last years. Among the 53 
pathways involved in the pathophysiology of asthma, the metabolism of nitric oxide (NO) 54 
also called the nitrate-nitrite-NO pathway has taken a growing place in this research field [1]. 55 
The NO metabolism is complex, and both NO measured by the exhaled fraction of NO (FENO) 56 
and NO-related compounds such as nitrites (NO2
−
) and nitrates (NO3
−
) are relevant biological 57 
markers that may help to better understand the patho-physiology of asthma and allergy [2].  58 
FENO is the most studied one, and it is commonly considered as a non-invasive indirect marker 59 
of airway inflammation [3]. Both epidemiological and clinical studies in adults showed 60 
increased level of FENO in children and adults with asthma, and positive associations between 61 
FENO and allergic sensitization are consistent over the studies, regardless of rhinitis or asthma 62 
[4]. Studies on associations between NO2
−
 and NO3
−
 levels with asthma, allergy or rhinitis 63 
have led to more conflicting results both in adults and children [5–17].  Until now, none of 64 
these studies has simultaneously performed measurements of EBC NO2
−
/NO3
−
 and FENO 65 
levels in the same subjects. Recently, in a large number of adults from the French 66 
Epidemiological study on Genetics and Environment of Asthma (EGEA), EBC NO2
−
/NO3
−
 67 
and FENO levels were found to be correlated in subjects without asthma  [18].  68 
Nitric oxide has different functions and roles in pathophysiology, which may be better 69 
explained by considering its compartmentalized production [19]. In this study, we compared 70 
the association between total NO2
−
/NO3
−
 levels measured in two compartments (plasma and 71 
exhaled breath condensate) and FENO levels with asthma, allergic sensitization and rhinitis 72 
among 523 adults from the EGEA study. We hypothesized  that the associations will be 73 
different depending on the compartments, biomarkers and outcomes studied. 74 
75 
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Methods  76 
Study design 77 
Data used for the analyses were collected in the framework of the 12-year follow-up of 78 
EGEA. EGEA is a French cohort study based on an initial group of asthma cases and their 79 
first-degree relatives, and controls (first survey, n=2047) [20]. The protocol and descriptive 80 
characteristics have been described previously [21,22]. A follow-up of the initial cohort was 81 
conducted between 2003 and 2007 [23]. Among the alive cohort (n=2002), 92% (n=1845) 82 
completed a short self-administered questionnaire and among them 1601 had a complete 83 
examination. All subjects responded to a questionnaire based on international standardized 84 
tools to diagnose asthma and to determine respiratory and allergic symptoms, treatments, and 85 
environmental exposures. The present cross-sectional analysis includes those who were adults 86 
at the second survey (≥ 16 years old, n=1570 adults) with available data on asthma, current 87 
rhinitis, allergic sensitization, and available measurements of exhaled breath condensate 88 
NO2
−
/NO3
−
 and FENO levels (n=523). Subjects included in the analyses were younger, 89 
reported more often ever asthma and current rhinitis, and had higher levels of NO2-/NO3- and 90 
Immunoglobulin E (IgE) than those not included in the analyses (n=1047). The two groups 91 
were similar for sex, smoking, current asthma status, allergic sensitization, lung function tests, 92 
and eosinophil (EOS) count (see Table 1 in supplementary data). 93 
Ethical approval was obtained from the relevant institutional review board committees 94 
(Cochin Port-Royal Hospital and Necker-Enfants Malades Hospital, Paris). Written informed 95 
consent was signed by all participants. 96 
97 
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Respiratory phenotypes 98 
Subjects with ever asthma were defined by a positive answer to either: “Have you ever had 99 
attacks of breathlessness at rest with wheezing?”, or “Have you ever had asthma attacks?”, or 100 
if they were recruited as asthmatic cases at the first survey.  101 
Allergic sensitization was defined by a positive skin prick test (SPT+) with a mean wheal 102 
diameter 3mm than the negative control for at least one of 12 aeroallergens (indoor: cat, 103 
Dermatophagoides pteronyssinus, Blattela germanica, outdoor: olive, birch, Parieteria 104 
judaica, timothy grass, Cupressus and ragweed pollen, and molds: Aspergillus, Cladosporium 105 
herbarum, Alternaria tenuis). Subjects were classified as sensitized if they have one or more 106 
SPT+. Current rhinitis was defined by a positive answer to one of the two questions: “Have 107 
you ever had rhinitis?" or " Have you ever had hay fever?” and a positive answer to “have 108 
you had sneezing problems or a runny nose in the past 12 months?” Allergic rhinitis was 109 
defined as having both current rhinitis and one or more SPT+. Subjects were also classified in 110 
three groups as non sensitized (no SPT+), sensitized only (having one or more SPT+ and no 111 
current rhinitis) and as having allergic rhinitis (one or more SPT+ and current rhinitis). 112 
Eosinophilia was defined as eosinophil count ≥5%. Details on other phenotypes are given in 113 
supplementary data. 114 
 115 
Biological phenotypes 116 
Exhaled breath condensate (EBC) was collected with an RTube™ according a standardized 117 
method. Briefly, the RTube (TM) was rinsed with deionized water and dried thoroughly. 118 
Participants breathed orally at tidal volumes into a mouthpiece attached to a cold condenser (-119 
20°C). They were seated comfortably with a headrest. All headrests and back seats were tilted 120 
slightly to avoid any saliva contamination during breathing maneuvers (see supplementary 121 
data for more details). 122 
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Total nitrite-nitrate (NO2
−
/NO3
−
) levels were measured in plasma and EBC as previously 123 
described [24]. All measurements were done in duplicate. Analytical intra-run imprecision 124 
was below 3%. Measurements with a coefficient of variation >15% and extreme outliers 125 
(n=7) were excluded from the analyses (see supplementary data for more details).  126 
Measurements of FENO were realized before other pulmonary function tests according to 127 
ATS/ERS recommendations (see supplementary data). The measurement was performed only 128 
in 3 of the 5 centers involved in the EGEA study, which explained in a large part the attrition 129 
on numbers of subjects included in the analysis compared to the total number. FENO level was 130 
measured at 50mL/s flow rate as previously described [23]. 131 
 132 
Statistical Methods 133 
Joint distribution of asthma, SPT+ and current rhinitis was shown with a Venn diagram 134 
(Figure 1). Total plasma and EBC NO2
−
/NO3
−
 and FENO levels were log10-transformed as a 135 
result of their skewed distribution.  136 
In the same study, we previously reported that plasma NO2
−
/NO3
−
 level was increased with 137 
leafy vegetable consumption and decreased in smokers and with storage time, that EBC 138 
NO2
−
/NO3
−
 level was decreased in smokers and with exposure to ambient ozone 139 
concentration [24], and that FENO level was associated with season of examination [23]. 140 
Furthermore, storage time and season of examination varied with centre. Therefore estimates 141 
were adjusted for 1) age, sex, smoking, leafy vegetable consumption and centre for plasma 142 
NO2
−
/NO3
−
, 2) age, sex, smoking, ambient ozone concentration and centre for EBC 143 
NO2
−
/NO3
−
, and 3) age, sex, height, smoking and centre for FENO. Since the ratio of higher 144 
oxides of nitrogen (HiNOx including NO2
−
 and NO3
−
) to NO
 
was reported be more 145 
informative than each measurement alone by Nguyen et al. [13], the (NO2
−
 + NO3
−
)/NO ratio 146 
(NOx/NO ratio) has also been studied.  147 
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As inhaled corticosteroids (ICS) use can decrease FENO levels, and as NO2
−
/NO3
−
 and FENO 148 
are biological markers involved in the same pathway, association between ICS use and EBC 149 
NO2
−
/NO3
−
 level was studied. Since increased body mass index (BMI)/obesity has been 150 
associated with lower FeNO level, estimates were also adjusted for BMI as a sensitivity 151 
analyses. 152 
Associations between total NO2
−
/NO3
−
 levels, FENO levels, and the NOx ratio (NO2
−
 + 153 
NO3
−
)/NO and asthma phenotypes, allergic sensitization and current rhinitis were estimated 154 
with linear regression models. Parameter estimates were assessed by using generalized 155 
estimating equations, with an exchangeable working correlation to account for the potential 156 
clustering within families (SAS MIXED procedure). The level of statistical significance was 157 
set at α=0.05. Two-sided P values were reported for all association estimates. All analyses 158 
were conducted using SAS software, version 9.3 (SAS Institute, Inc., Cary, NC, USA). 159 
 160 
Results 161 
The characteristics of the 523 adults according to their asthma status are summarized in Table 162 
1. As expected, subjects with asthma had significantly higher eosinophilia, lower FEV1% 163 
predicted, more often bronchial hyper-responsiveness (BHR), SPT+, and reported more often 164 
current rhinitis than subjects without asthma. After adjustment for age, sex and smoking, the 165 
following associations between asthma and eosinophilia (odds ratio (OR) 3.12, 95% 166 
confidence interval (CI, 1.72-5.66), FEV1% predicted (mean ± SD: 107.7 ± 10.5 vs. 97.5 ± 167 
11.0), BHR (OR, 4.18; 2.66-6.57), SPT+ (OR, 5.07; 3.32-7.72) and current rhinitis (OR, 4.62; 168 
3.11-6.85) were confirmed (all P<0.0005). EOS count, IgE and FENO levels were significantly 169 
higher in subjects with asthma than in those without (all P<0.0001). EBC NO2
−
/NO3
−
 level 170 
was unrelated to ICS use (data not shown, P value=0.5). 171 
 172 
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Pairwise association between EBC NO2
−
/NO3
−
, FENO levels and blood eosinophil counts 173 
EBC NO2
−
/NO3
−
 levels were unrelated with EOS, whereas FENO levels were positively 174 
associated with EOS in all subjects, both in non-sensitized and sensitized subjects (Table 2). 175 
In sensitized subjects, EBC NO2
−
/NO3
−
 was positively associated with FENO levels. 176 
The median FENO value in the population was 15.6 ppb (range 2.4  to 99.0 ppb). Stratification 177 
according to this median value showed positive and significant association between EBC 178 
NO2
−
/NO3
−
 level and allergic sensitization in subjects above the median only (2.66 (2.06-179 
3.43) vs. 1.64 (1.18-2.28), P=0.01 and 2.03 (1.52-2.71) vs. 1.76 (1.30-2.38), P=0.4 in subjects 180 
above and below the median respectively). 181 
 182 
Plasma and EBC NO2
−
/NO3
−
, FENO levels and asthma and asthma-related phenotypes 183 
Both plasma and EBC NO2
−
/NO3
−
 levels were unrelated to ever asthma, current asthma, 184 
symptomatic score, and asthma control (data not shown, all P values>0.3). Furthermore, 185 
plasma NO2
−
/NO3
−
 level was unrelated to allergic sensitization and current rhinitis.  186 
 Both plasma and EBC NO2
−
/NO3
−
 levels were unrelated to eosinophilic asthma nor to age at 187 
asthma onset (Table 3). As expected, a positive and significant association was observed 188 
between FENO level and eosinophilic asthma (Table 3) but no other significant association was 189 
observed.  190 
 191 
EBC NO2
−
/NO3
−
 and FENO levels, NOx/NO ratio and allergic sensitization 192 
A positive association at borderline significance was observed between EBC NO2
−
/NO3
−
 level 193 
and SPT+ (see Table 4). In a model adjusted for covariates, including asthma, EBC 194 
NO2
−
/NO3
−
 level was positively and significantly associated with SPT+, and a positive 195 
association at borderline significance was observed with current rhinitis. Furthermore, 196 
positive and gradual increases in EBC NO2
−
/NO3
− 
level were observed with SPTQ (see Figure 197 
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1 in supplementary data), and when subjects were classified in the following groups: no 198 
SPT+, SPT+ only, and both SPT+ and current rhinitis (see Table 4 and Figure 2). The median 199 
EBC NO2
−
/NO3
−
 value in our population was 2.25 µmol/mg proteins (range 1.12  to 4.98, 200 
Table 1). Stratification according to this median value showed positive and significant 201 
associations between subjects above the median value and 1) allergic sensitization (OR, 1.92; 202 
1.25-2.97, p=0.003), 2) current rhinitis (OR, 1.52; 1.01-2.28, p=0.04), and 3) SPT+ only or 203 
both SPT+ and current rhinitis versus no SPT+ (OR, 1.64; 1.01-2.66, p=0.04, and 2.16; 1.29-204 
3.59, p=0.003 respectively) in GEE regression models with adjustement for age, sex, 205 
smoking, ambient ozone concentration, asthma and centre. 206 
Similarly to EBC NO2
−
/NO3
−
, FENO level was also positively related to allergic sensitization 207 
expressed as SPT+ (Table 4), and gradually increased with SPTQ (see Figure online for 208 
details), and with allergic sensitization and current rhinitis. FENO was also significantly and 209 
positively associated with current rhinitis. The associations between FENO levels and SPT+, 210 
and current rhinitis were confirmed when BMI instead of height was added as covariate in the 211 
models (data not shown).   212 
No significant association were observed between the (NO2
−
 + NO3
−
)/NO ratio (NOx/NO 213 
ratio) and SPT+, current rhinitis or both (Table 4 and Figure 2). When analysing SPT+ to 214 
indoor, outdoor or molds allergens separately, EBC NO2
−
/NO3
−
 levels showed positive and 215 
significant associations with sensitization to molds allergens, and FENO levels were positively 216 
associated to indoor allergens (Table 4). 217 
218 
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Discussion 219 
The present study conducted on a large sample of adults with a precise phenotypic 220 
characterization shows for the first time the similarities and differences for the associations of 221 
both FENO and exhaled breath condensate NO2
−
/NO3
−
 levels with asthma, allergic 222 
sensitization and rhinitis. Results showed higher EBC NO2
−
/NO3
−
and FENO levels in subjects 223 
with allergic sensitization, with current rhinitis, and in particular when both are present. Only 224 
FENO levels were found to be higher with asthma. EBC NO2
−
/NO3
−
and FENO levels were 225 
positively associated in sensitized subjects only, and EBC NO2
−
/NO3
−
 levels were found to be 226 
associated with allergic sensitization in subjects with higher FENO levels only.  227 
The selection of the 523 subjects included in the present analyses was driven first by the 228 
random availability of the FENO measurements in three of the five participating centres [23], 229 
and secondly by the availability of the other variables of interest. Definition of asthma case is 230 
very precise in our study since asthmatic cases were recruited in chest clinics, and a procedure 231 
was set up to include true asthmatics, leading to a very limited risk of false positives. 232 
Prevalence of bronchial hyper-responsiveness, measured by a methacholine challenge test was 233 
quite high in subjects without asthma. A possible explanation is that part of the subjects 234 
without asthma are first degree relatives of asthma cases. Nevertheless, this result is 235 
consistent with the relatively considerable number of asymptomatic subjects with BHR 236 
reported in cross-sectional epidemiologic studies, ranging from 19.3 to 62.4%. Subjects 237 
included in the analyses had higher EBC NO2
−
/NO3
−
and FENO levels than non-selected 238 
subjects. Other limitations of the present study were those commonly related to cross-239 
sectional analyses of the data.  240 
We reported no association between NO2
−
/NO3
−
 level measured in plasma and any disease 241 
phenotypes. We previously reported that plasma and EBC NO2
−
/NO3
−
 levels were not 242 
correlated [18]. The metabolism of NO is complex, and the production of NO2
−
/NO3
− 
in 243 
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plasma differs from that in EBC due to their compartmentalization. In plasma NO2
−
/NO3
− 
244 
production derives from several sources, such as bacteria, enzymatic production and dietary 245 
sources [25]. In EBC ionized NO3
−
 and NO2
− 
(not volatile) may arise from NO after reaction 246 
with oxygen [26] or from activated immune cells present in the lining fluid of the lungs  [27]. 247 
Overall, the specificities of the NO metabolism in plasma and in EBC may partly explain the 248 
lack of association with any clinical phenotypes in plasma. Our results are consistent with the 249 
hypotheses of Villanueva and Giulivi [19], for whom the compartmentalized production of 250 
NO better explains its different functions and roles in pathophysiology. 251 
No association was found between total NO2
−
/NO3
− 
level in EBC and asthma phenotypes, as 252 
previously reported in other studies [8,14]. Contrary to our results, other studies have reported 253 
total NO2
−
/NO3
− 
level in EBC to be elevated in subjects with asthma as compared to healthy 254 
non-smoking subjects [17], healthy non-atopic controls [5], or controls [9]. These conflicting 255 
results may be due to the very small number of subjects included in these studies, the various 256 
methodologies used for measuring NO2
−
 and NO3
−
 levels, the choice of the reference group 257 
for comparisons and other differences such as those related to phenotypes definition. Beside, 258 
information regarding allergic sensitization was not available or subjects were defined as 259 
asthmatics if they had both asthma and allergy, suggesting that the increase in NO2
−
/NO3
− 
260 
level could be more related to allergy than to asthma. Furthermore, none of these previous 261 
studies have expressed the NO2
−
/NO3
− 
level divided by the amount of proteins. As reported by 262 
Gessner and Wirtz [28], the measurement of total protein in EBC is important to confirm that 263 
protein and peptide markers are comparable between studies. They should always be 264 
performed in addition to specific markers investigated, and we previously found that 265 
NO2
−
/NO3
− 
level in EBC was positively related to protein concentration in our study [29].  266 
As reported in the literature [4,30], positive associations between FENO level and asthma, 267 
allergic sensitization, and current rhinitis were found in this study. To our knowledge, our 268 
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study reported for the first time similarities and differences for the associations of both FENO 269 
and exhaled breath condensate NO2
−
/NO3
−
 levels with asthma, allergic sensitization and 270 
current rhinitis. We found positive associations between EBC NO2
−
/NO3
−
 and FENO levels in 271 
sensitized subjects, and between EBC NO2
−
/NO3
−
 levels with allergic sensitization in subjects 272 
with higher FENO levels. Consistently, we found that both EBC NO2
−
/NO3
−
 and FENO levels 273 
increased with allergic sensitization, with the number of SPT+, and that gradual relationships 274 
were observed between sensitized subjects only and those with both allergic sensitization and 275 
rhinitis. An immediate practical utility could not be inferred from the results obtained in the 276 
framework of this epidemiologic study; but taken together, our results suggest that EBC 277 
NO2
−
/NO3
−
 and FENO levels may be considered as biological markers of intensity of allergic 278 
sensitization and rhinitis. Longitudinal studies are also needed to better understand the role of 279 
these biomarkers,  in line with the idea that part of the "allergic march" involves oxidative and 280 
nitrosative processes. 281 
By considering together EBC NO2
−
/NO3
−
 and FENO levels rather than each alone, our results 282 
provided complementary interesting information. To go further, we also studied the 283 
association between the NOx(NO2
−
 + NO3
−
)/NO ratio and allergic sensitization.  284 
Unfortunately, this ratio was not more informative than considering the measurement of EBC 285 
NO2
−
/NO3
− 
alone. Contrary to our results, a ratio including also S-nitrosothiols (NO2
−
 + NO3
−
 286 
+ S-nitrosothiols)/NO was found to better evaluate inflammation in a case-control study on 287 
asthma [13] than the measurement of each oxide of nitrogen alone. This discrepancy in the 288 
results may be partly explained by the lack of measurement of S-nitrosothiols in our study, by 289 
the fact that we studied allergic sensitization rather than inflammation, and/or by differences 290 
in study designs. 291 
Overall, even if our results need to be replicated, they may suggest a role of the nitrate-nitrite-292 
NO pathway in allergic sensitization. We suggest that exposure to allergens results in uptake 293 
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and proceeding by dendritic cells inducing the development of Th2 cells in sensitized 294 
individuals. Recent evidence indicates that airway epithelium also plays an important role in 295 
the allergic airway response by the release of IL-25, IL-33 and TSLP which activate dendritic 296 
cells, basophils, eosinophils and Th2 cells [31,32]. TSLP, IL-25 and IL-33 promote 297 
eosinophilia in airway mucosa by inducing IL-5 production. Eosinophilic airway 298 
inflammation may increase the NO concentration and subsequently produces the formation of 299 
NO2
−
, NO3
−
 and reactive nitrogen species in EBC. 300 
The results reported in this study highlight the complexity of NO metabolism. Initially 301 
considered completely inert, it is now apparent that nitrate and nitrite are physiologically 302 
recycled in blood and tissues to form NO and other bioactive nitrogen oxides [2]. They may 303 
be viewed as storage pools for NO-like bioactivity, thereby complementing the NO synthase 304 
(NOS)-dependent pathway. NO and related compounds are produced by a wide variety of 305 
residential and inflammatory cells in the respiratory tract[33]. In response to allergens, both 306 
dendritic cells (DCs) and airway epithelial cells are stimulated, and release various cytokines 307 
which activate DCs, basophils, mast cells, eosinophils and Th2 cells, leading to eosinophil 308 
activation and proliferation [34]. We previously reported that FENO level was positively 309 
associated with blood eosinophil counts [18], and there are in vitro evidences that human 310 
blood eosinophils produce NO and participate in the regulation of the NO pool in pulmonary 311 
tissues [35,36]. Moreover, NO modulates the Th1/Th2 balance by favoring Th2 response and 312 
IL-5 production and thus recruiting eosinophils into the airways. Nevertheless, even if EBC 313 
NO2
−
/NO3
−
 level can be viewed as a potential biological marker of allergy in our study, its 314 
specific role remains unknown, and mechanistic studies are required. As suggested through 315 
the results of the present study, and as reported by Erzurum et al. [37], the complexity of the 316 
nitrate-nitrite-NO pathway provide evidence that more targeted biological markers are needed 317 
to put them into a global scheme that help us to identify a type of response or phenotype for a 318 
 15 
given patient, requiring the integration of multiple factors in a system biology approach. 319 
Further studies are also warranted to better investigate the associations we observed in this 320 
epidemiological study, and the potential for a practical utility of our findings. 321 
In conclusion, we report for the first time in a large epidemiological study that both total 322 
NO2
−
/NO3
−
 and FENO levels in exhaled breath condensate are associated with allergic 323 
sensitization and rhinitis. The role of the nitrate-nitrite-NO pathway in the "allergic march" 324 
need to be further investigated in longitudinal studies. However, contrary to what has been 325 
shown with FENO, we did not find an association of this biomarker with clinical phenotypes 326 
of asthma. Studying both exhaled fraction of NO and EBC NO2
−
/NO3
−
 may be helpful for 327 
disentangle the associations between NO metabolism and asthma, allergic sensitization and 328 
rhinitis. 329 
330 
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Figure legends 362 
Figure 1. Concordance of ever asthma, allergic sensitization (SPT+) and current rhinitis 363 
(Proportional Venn Diagram). 364 
Data on current rhinitis was missing for four participants without allergic sensitization and 365 
asthma, one participant with asthma and one participant with allergic sensitization (n=517).  366 
 367 
Figure 2. Associations between FeNO, total NO2
−
/NO3
− 
and (NO2
−
 + NO3
−
)/NO ratio levels 368 
in exhaled breath condensate with allergic sensitization, current rhinitis and both. 369 
Regression coefficients (Beta) and 95%CI for associations between FeNO, total NO2
−
/NO3
− 
370 
levels, (NO2
−
 + NO3
−
)/NO ratio and allergic sensitization, current rhinitis and both, estimated 371 
through GEE linear regression methods, and adjusted for covariates: age, sex, smoking, 372 
ambient ozone concentration, asthma and centre for NO2
−
/NO3
− 
level; age, sex, smoking, 373 
height, asthma and centre for FeNO level; age, sex, smoking, asthma and centre for (NO2
−
 + 374 
NO3
−
)/NO ratio. 375 
 376 
377 
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Table 1. Characteristics of subjects according to asthma status 
 All subjects 
N=523 
Subjects 
without asthma 
N=268 
Subjects 
 with asthma  
N=255 
 
 P value 
Age, year, mean  SD 39.9  16.6 43.2  15.9  36.5  16.8 <0.0001 
Sex, women, % 51.0 57.5 44.3 0.003 
Body mass index (BMI), kg/m², mean  SD 23.7  3.9 23.8  3.8 23.5  4.0 0.4 
Smoking habits, % 
 Never smokers 
 Ex-smokers 
 Current smokers 
 
51.6 
25.3 
23.1 
 
49.6 
28.0 
22.4 
 
53.7 
22.4 
23.9 
 
 
0.3 
Asthma     
Ever asthma, % 48.7 - 100.0 - 
Current asthma, % 40.5 - 83.1 - 
Age at asthma onset , % 
[0-4] years 
]4-16] years 
>16 years 
 
- 
- 
- 
 
- 
- 
- 
237 
36.7 
39.7 
23.6 
 
 
- 
Symptomatic score, n 
mean  SD 
517 
1.17  1.35 
266 
0.51  0.81 
251 
1.86  1.46 
 
<0.0001 
Asthma control, GINA 2006, %     
 26 
 Controlled 
 Partly controlled 
 uncontrolled 
20.6 
10.7 
8.2 
 
- 
42.3 
22.0 
16.9 
 
- 
Eosinophilia (cells>5%), % 12.4 6.7 18.4 <0.0001 
Eosinophilic asthma (≥250 cells/mm²), % - - 36.5 - 
FEV1 % predicted, mean  SD 103.4  17.2 108.5  16.6 98.0  17.5 <0.0001 
Methacholine test*, PD20≤4 mg, % 45.4 28.8 65.1 <0.0001 
Inhaled corticosteroids, last 12 months, % 20.6 2.2 40.0 <0.0001 
Inhaled corticosteroids, last 3 months, % 7.3 0.0 14.9 - 
SPT+ and current rhinitis     
SPT+, % 58.1 38.8 78.4 <0.0001 
SPTQ, number of SPT+, median [Q1-Q3] 1 [0-3] 0 [0-1] 2 [1-4] <0.0001 
Current rhinitis, % 39.2 22.3 56.9 <0.0001 
SPT+ and Current rhinitis, % 32.9 18.0 48.6 <0.0001 
Biological phenotypes, GM [Q1-Q3]     
EBC NO2
−
/NO3
−
, µmol/mg proteins 2.25 [1.12-4.98] 2.33 [1.15-4.81] 2.16 [1.13-5.11] 0.5 
FeNO, ppb 15.1 [10.0-23.0] 13.2 [9.00-18.8] 17.5 [11.5-29.6] <0.0001 
EBC (NO2
−
 + NO3
−
)/NO ratio , median [Q1-Q3] 0.30 [0.04-0.60] 0.34 [0.06-0.61] 0.26 [0.04-0.58] 0.16 
Plasma NO2
−
/NO3
−
, µM 510 
39.1 [28.0-53.7] 
263 
38.9 [26.3-56.4] 
247 
39.3 [29.1-53.2] 
 
0.8 
Eosinophils, n 505 256 249  
 27 
cells/mm
3
 170 [100-280] 145 [100-200] 199 [100-300] <0.0001 
IgE, IU/ml 81.7 [28.8-226] 49.8 [19.4-128] 137 [59.0-332] <0.0001 
SPT+: a mean wheal diameter 3mm than the negative control for at least one of 12 aeroallergens. 
The symptomatic score is based on the number of asthma symptoms (wheeze and breathlessness, woken with chest tightness, woken by attack of 
shortness of breath, attack of shortness of breath at rest, attack of shortness of breath after exercise). 
 *Methacholine challenge test was not performed if baseline FEV1 <80% predicted. GM= geometric mean, Q1-Q3=first and third quartile. 
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Table 2. Pair-wise association of EBC NO2-NO3 , FeNO levels and eosinophil count in all subjects, and according to allergic sensitization 
  EBC NO2
−
/NO3
−
 level, µmol/mg proteins 
a
  FeNO level, ppb 
b
  
 N Estimate SD p-value N Estimate SD p-value 
All subjects             
Eosinophils, cells/mm
3
 492 0.14 0.09 0.10 505 0.25 0.04  <0.0001 
            
FeNO level, ppb 510 0.14 0.08 0.10       
          
Non-sensitized subjects            
Eosinophils, cells/mm
3
 204 0.15 0.13 0.3 208 0.15 0.05  0.01 
            
FeNO level, ppb 215 -0.17 0.15 0.3       
            
Sensitized subjects                  
Eosinophils, cells/mm
3
 288 0.15 0.11 0.2 297 0.31 0.06  <0.0001 
            
FeNO level, ppb 295 0.21 0.10 0.04          
Estimates are adjusted for
 a
: age, sex, smoking, ambient ozone concentration, asthma and centre; 
b
: age, sex, smoking, height, asthma and centre 
(GEE linear regression methods). 
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Table 3. Associations between FeNO, total NO2
−
/NO3
− 
and ratio levels in exhaled breath condensate with eosinophilic asthma and age at onset  
 EBC NO2
−
/NO3
−
 level, 
µmol/mg proteins 
a
 
 FeNO level, ppb 
b
  (NO2
−
 + NO3
−
)/NO 
ratio level 
c
 
  
  N GM  95%CI p-value N GM 95%CI p-value N mean 95%CI p-value 
Eosinophilic asthma, No 
 Yes 
162 
93 
1.97 
2.54 
1.61;2.41 
1.98;3.26 
 
0.12 
162 
93 
15.4 
22.0 
13.7;17.2 
19.0;25.5 
 
0.0002 
162 
93 
0.25 
0.30 
0.16;0.34 
0.22;0.39 
 
0.4 
Age at onset,  [0-4] years 
 ]4-16] years 
 >16 years 
87 
94 
56 
2.49 
2.09 
1.99 
1.93;3.21 
1.60;2.75 
1.38;2.87 
 
0.3 
d
 
87 
94 
56 
17.7 
17.8 
16.8 
15.1;20.6 
15.3;20.7 
13.6;20.8 
 
0.7 
d
 
87 
94 
56 
0.33 
0.25 
0.26 
0.22;0.43 
0.14;0.35 
0.11;0.41 
 
0.4 
d
 
Model adjusted for all covariates            
Eosinophilic asthma, No 
 Yes 
157 
92 
1.79 
2.30 
1.35;2.37 
1.66;3.18 
 
0.13 
162 
93 
16.8 
23.9 
14.6;19.4 
20.2;28.3 
 
<0.0001 
162 
93 
0.20 
0.27 
0.09;0.32 
0.14;0.40 
 
0.3 
Age at onset,  [0-4] years 
 ]4-16] years 
 >16 years 
84 
93 
56 
2.26 
1.91 
1.59 
1.60;3.20 
1.37;2.67 
1.02;2.00 
 
0.15 
d
 
87 
94 
56 
18.8 
19.4 
18.4 
15.6;22.6 
16.3;23.1 
14.6;23.3 
 
0.9 
d
 
87 
94 
56 
0.30 
0.21 
0.17 
0.17;0.43 
0.08;0.34 
0.01;0.34 
 
0.15 
d
  
Results are expressed as GM or mean (and 95%CI). 
Abbreviations: GM: geometric mean; CI: Confidence Interval; EBC: Exhaled Breath Condensate; NO2
−
/NO3
−
: nitrite/nitrate.
 
a
: adjusted for age, sex, smoking, ambient ozone concentration, asthma and centre; 
b
: adjusted for age, sex, smoking, height, asthma and centre 
(GEE regression methods); 
c
: adjusted for age, sex, smoking, asthma and centre; 
d
: p-value for trend. 
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Table 4. Associations between FeNO, total NO2
−
/NO3
− 
and ratio levels in exhaled breath condensate with allergic sensitization  
 EBC NO2
−
/NO3
−
 level, 
µmol/mg proteins 
a
 
 FeNO level, ppb 
b
  (NO2
−
 + NO3
−
)/NO 
ratio level 
c
 
  
  N GM  95%CI p-value N GM 95%CI p-value N mean 95%CI p-value 
Allergic sensitization, No 
 Yes 
219 
304 
2.03 
2.41 
1.73;2.38 
2.11;2.76 
 
0.10 
219 
304 
12.6 
17.3 
11.6;13.6 
15.9;18.8 
 
<0.0001 
219 
304 
0.29 
0.31 
11.6;13.6 
15.9;18.8 
 
0.7 
Current rhinitis No 
 Yes 
312 
205 
2.20 
2.30 
1.93;2.51 
1.94;2.72 
 
0.7 
312 
205 
13.8 
17.7 
12.8;14.8 
16.1;19.6 
 
<0.0001 
312 
205 
0.30 
0.29 
0.25;0.36 
0.22;0.36 
 
0.8 
SPT+ and Current rhinitis, 
 No 
 SPT+ 
 Both 
219 
131 
172 
2.03 
2.34 
2.47 
1.73;2.38 
1.90;2.89 
2.07;2.94 
 
0.10 
d
 
219 
131 
172 
12.6 
15.9 
18.4 
11.6;13.6 
14.0;18.0 
16.5;20.5 
 
<0.0001 
d
 
219 
131 
172 
0.29 
0.29 
0.32 
0.22;0.36 
0.21;0.38 
0.25;0.39 
 
0.6 
d
 
Model adjusted for centre only            
Allergic sensitization, No 
 Yes 
Current rhinitis No 
 Yes 
219 
304 
312 
205 
1.87 
2.26 
1.97 
2.26 
1.55; 2.26 
1.92; 2.66 
1.66;2.33 
1.87;2.72 
 
0.06 
 
0.19 
219 
304 
312 
205 
14.2 
19.4 
15.2 
20.1 
12.8; 15.7 
17.7; 21.1 
13.9;16.7 
18.2;22.2 
 
<0.0001 
 
<0.0001 
219 
304 
312 
205 
0.25 
0.27 
0.25 
0.27 
0.17;0.33 
0.20;0.34 
0.18;0.32 
0.19;0.35 
 
0.6 
 
0.7 
SPT+ and Current rhinitis, 
 No 
 SPT+ 
 Both 
219 
131 
172 
1.87 
2.12 
2.37 
1.55;2.26 
1.70;2.64 
1.94;2.89 
 
0.04 
d
 
219 
131 
172 
14.2 
17.5 
20.7 
12.8;15.7 
15.6;19.8 
18.6;23.0 
 
<0.0001 
d
 
219 
131 
172 
0.25 
0.24 
0.29 
0.17;0.33 
0.15;0.34 
0.20;0.37 
 
0.4 
d
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Model adjusted for all covariates            
Allergic sensitization, No 
 Yes 
215 
295 
1.72 
2.36 
1.38; 2.14 
1.96; 2.84 
 
0.008 
219 
304 
14.8 
18.3 
13.3; 16.5 
16.7; 20.0 
 
0.0006 
219 
304 
0.21 
0.29 
0.13;0.30 
0.22;0.36 
 
0.10 
Current rhinitis No 
 Yes 
305 
199 
1.90 
2.31 
1.57;2.31 
1.87;2.84 
 
0.09 
312 
205 
15.4 
19.2 
14.0;16.9 
17.4;21.2 
 
0.0001 
312 
205 
0.24 
0.28 
0.16;0.31 
0.20;0.36 
 
0.3 
SPT+ and Current rhinitis, 
 No 
 SPT+ 
 Both 
215 
128 
166 
1.71 
2.17 
2.50 
1.37;2.13 
1.70;2.76 
2.01;3.12 
 
0.005 
d
 
219 
131 
172 
14.8 
16.4 
19.7 
13.3;16.5 
14.6;18.4 
17.7;21.9 
 
<0.0001 
d
 
219 
131 
172 
0.21 
0.26 
0.32 
0.12;0.29 
0.17;0.36 
0.23;0.40 
 
0.06 
d
 
Allergic sensitization (Indoor only)            
 No 
 Yes 
215 
76 
1.66 
2.03 
1.28; 2.16 
1.47; 2.81 
 
0.2 
219 
80 
14.2 
17.1 
12.7; 15.9 
14.8; 19.7 
 
0.02 
219 
80 
0.21 
0.26 
0.10;0.31 
0.13;0.40 
 
0.4 
Allergic sensitization (Outdoor only)            
 No 
 Yes 
215 
45 
1.66 
1.78 
1.28; 2.15 
1.21; 2.62 
 
0.7 
219 
46 
14.6 
17.2 
13.2; 16.3 
14.6; 20.2 
 
0.06 
219 
46 
0.20 
0.20 
0.09;0.31 
0.03;0.36 
 
0.9 
Allergic sensitization (Molds only)            
 No 
 Yes 
217 
7 
1.58 
3.96 
1.20; 2.06 
1.69; 9.29 
 
0.04 
219 
7 
14.5 
21.2 
13.0; 16.2 
14.6; 30.6 
 
0.06 
219 
7 
0.18 
0.49 
0.07;0.30 
0.11;0.87 
 
0.12 
Results are expressed as GM or mean (and 95%CI). 
Abbreviations: GM: geometric mean; CI: Confidence Interval; EBC: Exhaled Breath Condensate; NO2
−
/NO3
−
: nitrite/nitrate.
 
a
: adjusted for age, sex, smoking, ambient ozone concentration, asthma and centre; 
b
: adjusted for age, sex, smoking, height, asthma and centre 
(GEE regression methods); 
c
: adjusted for age, sex, smoking, asthma and centre; 
d
: p value for trend. 
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Figure 1 
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